# Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial

Study · id `cardio:ct-nct02168829` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02168829](<https://clinicaltrials.gov/study/NCT02168829>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02168829

Browse, organ or system: Heart; Brain  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1284 participants.

## Technical summary

Registry record NCT02168829. Randomized; no masking; primary purpose prevention. Start 2016-01 (actual); primary completion 2025-08-14 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 1284 participants (enrolled count; ClinicalTrials.gov record NCT02168829, source copy `cardio:ctgov-nct02168829-2025-10-06`, retrieved 2026-10-26)
- Started: 2016-01 (actual) (ClinicalTrials.gov record NCT02168829, source copy `cardio:ctgov-nct02168829-2025-10-06`, retrieved 2026-10-26)
- Primary completion: 2025-08-14 (actual) (ClinicalTrials.gov record NCT02168829, source copy `cardio:ctgov-nct02168829-2025-10-06`, retrieved 2026-10-26)
- Completion: 2025-08-14 (actual) (ClinicalTrials.gov record NCT02168829, source copy `cardio:ctgov-nct02168829-2025-10-06`, retrieved 2026-10-26)
- Countries: Australia; Belgium; Canada; China; Germany; Israel (ClinicalTrials.gov record NCT02168829, source copy `cardio:ctgov-nct02168829-2025-10-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02168829-2025-10-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial
- Acronym: OCEAN
- Condition: Atrial Fibrillation
- Condition: Stroke
- Intervention (Drug): Rivaroxaban
- Intervention (Drug): Acetylsalicylic acid
- Lead sponsor: Ottawa Heart Institute Research Corporation
- Lead sponsor class: OTHER
- Collaborator: Canadian Institutes of Health Research (CIHR)
- Collaborator class: OTHER\_GOV
- Collaborator: Bayer
- Collaborator class: INDUSTRY
- Collaborator: Biotronik Canada Inc
- Collaborator class: INDUSTRY
- Collaborator: Abbott
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Rivaroxaban (`cardio:rivaroxaban`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)
- Registry lists this organization as the lead sponsor: Ottawa Heart Institute Research Corporation (`cardio:org-ottawa-heart-institute-research-corporation`)
- Registry lists this organization as a collaborator: Canadian Institutes of Health Research (CIHR) (`cardio:org-canadian-institutes-of-health-research-cihr`)
- Registry lists this organization as a collaborator: Bayer (`cardio:bayer`)
- Registry lists this organization as a collaborator: Abbott (`cardio:abbott`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation (`cardio:pubmed-41211931`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 7d410ba96a40f71c0c537c13c946368f7790033b5036e934d9ff47d0a2e58927
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
